Fighting antimicrobial resistance in sexually transmitted infections with targeted diagnostics

Antimicrobial resistance (AMR) has become one of the most pressing public health crises, with sexually transmitted infections (STIs) of all types rapidly becoming resistant to treatments.

One such infection of pressing concern is Mycoplasma genitalium, otherwise known as MG, which can cause non-specific urethritis (NSU) in men and pelvic inflammatory disease (PID) in women.

In this SelectScience webinar, three experts discuss how they combined their expertise to deliver a resistance-guided therapy approach for the successful treatment and management of sexually-transmitted infections (STIs), particularly in Mycoplasma genitalium, achieving 96% cure rates.

Key learning objectives

• Acquire new diagnostic approaches to combatting antimicrobial resistance
• Learn what sort of clinical outcomes can be expected by introducing resistance-guided therapy
• Discover the advantages of taking a multiplex approach to STI diagnostics
• Explore the future for antimicrobial resistance stewardship enabled by resistance-guided therapy

Who should attend?

• Researchers and clinicians working in the field of sexual and public health
• Molecular diagnostic manufacturers working in the field of infectious disease

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.